NCT05310188 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Afzali S, Taheri SK, Seifrabiei M
Butyrylcholinesterase level in poisoned patients with phosphide compounds. Caspian J Intern Med. 2019 Fall;10(4):458-462. doi: 10.22088/cjim.10.4.458.
Boedeker W, Watts M, Clausing P, Marquez E
The global distribution of acute unintentional pesticide poisoning: estimations based on a systematic review. BMC Public Health. 2020 Dec 7;20(1):1875. doi: 10.1186/s12889-020-09939-0.
Dungdung A, Kumar A, Kumar B, Preetam M, Tara RK, Saba MK
Correlation and prognostic significance of serum amylase, serum lipase, and plasma cholinesterase in acute organophosphorus poisoning. J Family Med Prim Care. 2020 Apr 30;9(4):1873-1877. doi: 10.4103/jfmpc.jfmpc_205_20. eCollection 2020 Apr.
Mehrpour O, Jafarzadeh M, Abdollahi M
A systematic review of aluminium phosphide poisoning. Arh Hig Rada Toksikol. 2012 Mar;63(1):61-73. doi: 10.2478/10004-1254-63-2012-2182. Review.
Mu Y, Hu B, Gao N, Pang L
Prognostic value of the neutrophil-to-lymphocyte ratio in acute organophosphorus pesticide poisoning. Open Life Sci. 2021 Jul 15;16(1):703-710. doi: 10.1515/biol-2021-0069. eCollection 2021.

Diagnostic and Prognostic Values of Cholinesterase, Amylase, Lipase and Neutrophil-to-lymphocyte Ratio in Acute Pesticide Poisoning Cases

Clinical trial NCT05310188 - References